Close Menu

NEW YORK — Fujitsu Laboratories and Aichi Cancer Center announced on Friday that they have signed an agreement to develop technologies for cancer genome data analysis.

The partners said they will use genomic and clinical cancer data, primarily on solid tumors, to develop artificial intelligence-based technologies for interpreting cancer genome data, with a focus on linking genetic profiles with treatment responses.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.